Where is MoonLake located?

MoonLake is headquartered in Zug, Switzerland.

How many employees does MoonLake have?

As of Sep 30, 2026, the latest employee count at MoonLake is 149.

Where does MoonLake rank among its competitors?

MoonLake ranks 99th amongst 450 active competitors, of which 139 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Evommune, which secured $125M in Feb, 2026.

Who are the top competitors of MoonLake?

MoonLake's top competitors include argenx, Vor Biopharma and Upstream Bio. Among them, Evommune secured the most recent funding round in February, 2026.

MoonLake - 2026 Company Profile, Team, Competitors & Financials

MoonLake is a public company based in Zug (Switzerland), founded in 2021 by Kristian Reich. It operates as a Developer of immunotherapies for inflammatory skin and joint diseases. The company has 450 active competitors, including 139 funded and 98 that have exited. Its top competitors include companies like argenx, Vor Biopharma and Upstream Bio.

Company Details

Developer of immunotherapies for inflammatory skin and joint diseases. The company's lead candidate Sonelokimab is a tri-specific IL17A/F nanobody that specifically targets IL17A and IL17F. It is used for the treatment of psoriasis, hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis.

Website: moonlaketx.com
Email ID: *****@moonlaketx.com

Key Metrics

Founded Year

2021

Location

Zug, Switzerland

Stage

Public

Ranked

99^th among 450 active competitors

Employee Count

149 as on Sep 30, 2026

Similar Companies

argenx & 535 more

Exit Details

Public

View MoonLake's full profile

MoonLake is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MOONLAKE IMMUNOTHERAPEUTICS CIN: 1821586 , United States, Active		-	-	-

MoonLake got listed on Apr 06, 2023.

Click here to take a look at MoonLake's IPO in detail

MoonLake is a funded company.

The founders of MoonLake is Kristian Reich.

Here are the details of MoonLake's key team members:

Kristian Reich: Founder of MoonLake.
Contact Info: 1 email address

View details of MoonLake's Founder profiles and Board Members

MoonLake's employee count trend

MoonLake has 149 employees as of Sep 26. Here is MoonLake's employee count trend over the years:

Uncover MoonLake's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MoonLake include argenx, Vor Biopharma and Upstream Bio. Here is the list of Top 10 competitors of MoonLake, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
2nd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	69/100
3rd	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	67/100
4th	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
5th	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
6th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
7th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
8th	Alumis 2003, San Francisco (United States), Public	Developer of therapeutics for the treatment of auto-immune disease	$529M	Foresite Capital, VenBio & 15 others	65/100
9th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, Valence Life Sciences & 11 others	64/100
10th	Vyome Therapeutics 2010, Princeton (United States), Public	Developer of therapeutics for the immuno-inflammatory conditions	$62.9M	Perceptive Advisors, Iron Pillar & 11 others	64/100
99th	MoonLake 2021, Zug (Switzerland), Public	Developer of immunotherapies for inflammatory skin and joint diseases	-	-	44/100